The features of SCD plus include (Jessen et al., 2014) subjective decline limited only to memory rather than other cognitive domains, complaints of SCD within the last 5 years, an age at onset of SCD ≥ 60 years, concerns (memory loss) associated with SCD, complaints of feeling worse than others in the same age group, confirmation of cognitive decline by an informant, and the presence of the apolipoprotein E-ε4 (APOE-ε4) genotype and other biomarker evidence for AD. The gene discussed is APOE; the disease is Alzheimer disease.